

FOI 4890 - Metastatic breast, lung and renal cell cancer data

Questions	Time Period	Response	
1. Within your health trust how many metastatic breast cancer patients are currently [within the past 6 months] being treated, with any therapy, surgery or palliative care.		We are unable to answer this question in full. However we are able to provide metastatic breast cancer patients admitted and treated as inpatients at the Trust. Please note that patients treated with palliative care and oral chemotherapy are not included in the figures below.	
Metastatic breast cancer inpatients	Feb 2019 to July 2019	46 patients	
2. Within your health trust how many breast cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments; •disodium pamidronate (Aredia) •ibandronic acid or ibandronate (Bondronat) •sodium clodronate (Bonefos, Clasteon, Loron) •zoledronic acid or zoledronate (Zometa) •denosumab (Xgeva)	Feb 2019 to July 2019	Drug Name	Total patients treated
		disodium pamidronate (Aredia)	0
		ibandronic acid or ibandronate (Bondronat)	0
		sodium clodronate (Bonefos, Clasteon, Loron)	0
		zoledronic acid or zoledronate (Zometa)	20
		denosumab (Xgeva)	15
3. Within your health trust how many breast cancer patients are currently [within the past 6 months] being treated with adjuvant therapy with the following treatments;	Feb 2019 to July 2019	Drug Name	Total patients treated
		disodium pamidronate (Aredia)	0
		ibandronic acid or ibandronate (Bondronat)	0
		zoledronic acid or zoledronate (Zometa)	2
4. Within your health trust how many metastatic lung cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.		We are unable to answer this question in full. However we are able to provide metastatic lung cancer patients admitted and treated as inpatients at the Trust. Please note that patients treated with palliative care and oral chemotherapy are not included in the figures below.	
Metastatic lung cancer inpatients	Feb 2019 to July 2019	38	
5. Within your health trust how many lung cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments; •disodium pamidronate (Aredia) •ibandronic acid or ibandronate (Bondronat) •sodium clodronate (Bonefos, Clasteon, Loron) •zoledronic acid or zoledronate (Zometa) •denosumab (Xgeva)	Feb 2019 to July 2019	Drug Name	Total patients treated
		disodium pamidronate (Aredia)	0
		ibandronic acid or ibandronate (Bondronat)	0
		sodium clodronate (Bonefos, Clasteon, Loron)	0
		zoledronic acid or zoledronate (Zometa)	0
		denosumab (Xgeva)	0

<p>6. Within your health trust how many metastatic renal cell cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.</p>	<p>We are unable to answer this question in full. However we are able to provide metastatic renal cancer patients admitted and treated as inpatients at the Trust. Please note that patients treated with palliative care and oral chemotherapy are not included in the figures below.</p>		
<p>Metastatic renal cell cancer inpatients</p>	<p>Feb 2019 to July 2019</p>	<p>3</p>	
<p>7. Within your health trust how many renal cell carcinoma [RCC] patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;</p> <ul style="list-style-type: none"> •disodium pamidronate (Aredia) •ibandronic acid or ibandronate (Bondronat) •sodium clodronate (Bonefos, Clasteon, Loron) •zoledronic acid or zoledronate (Zometa) •denosumab (Xgeva) 	<p>Feb 2019 to July 2019</p>	<p>Drug Name</p>	<p>Total patients treated</p>
		<p>disodium pamidronate (Aredia)</p>	<p>0</p>
		<p>ibandronic acid or ibandronate (Bondronat)</p>	<p>0</p>
		<p>sodium clodronate (Bonefos, Clasteon, Loron)</p>	<p>0</p>
		<p>zoledronic acid or zoledronate (Zometa)</p>	<p>0</p>
		<p>denosumab (Xgeva)</p>	<p>0</p>